From complexity to clarity. From data to breakthroughs.
In biopharma, every insight gained faster means a potential therapy delivered sooner. Excelra helps you make that leap—by transforming the world’s biomedical data into decision-ready intelligence.
We unify science, data, and technology to accelerate discovery and development across the drug pipeline. From early research to regulatory submission, we help you work smarter, not just faster.
The result? Smarter, faster, and more sustainable innovation in crop and livestock genetics.
Our Services
Our domain experts and experienced engineers deliver a comprehensive, end-to-end service portfolio tailored for the biopharma industry. We seamlessly integrate scalable bioinformatics, workflow automation, and robust data platform engineering to accelerate drug discovery and development. By combining digital consulting with AI and GenAI capabilities, we empower biopharma teams to uncover novel insights, streamline R&D processes, and enhance clinical outcomes. Our advanced data products and LLM-driven solutions transform complex biomedical data into actionable intelligence—enabling faster, smarter, and more efficient decision-making across the therapeutic lifecycle.
-
Scalable bioinformatics & analytics
From target ID to indication expansion—Excelra provides mechanistic and translational insights through integrative multi-omics analysis, biomarker discovery, drug repurposing, and response prediction.
-
Workflow integration & automation
Enable seamless collaboration between discovery teams, translational scientists, and CROs with integrated workflows across CTMS, ePRO, ELNs, LIMS, and OMICS tools—delivering up to 20% productivity gains.
-
Data platform engineering
Build a modern R&D backbone with FAIR-compliant infrastructure, domain-specific ontologies, and cloud-native data platforms that make your data findable, accessible, interoperable, and reusable.
-
Digital consulting & AI integration
Our experts assess your scientific workflows and digital maturity to help embed AI agents and automation tools, delivering transformation that’s scalable, secure, and results-driven.
-
Data products
Off-the-shelf and custom datasets that power advanced analytics and AI-driven discovery. Includes Excelra’s GOSTAR™ knowledgebases—covering small molecules, large molecules, and targeted protein degraders—used globally to accelerate compound screening, SAR analysis, and AI model development.
-
GenAI & LLM services for biopharma
Accelerate R&D, regulatory, and clinical workflows with GenAI and large language models—powering scientific search, regulatory document automation, predictive analytics, and AI copilots—all seamlessly integrated into your existing systems.
Explore GOSTAR™ for biopharma
The industry’s most comprehensive SAR database—curated for AI, trusted by pharma.
- GOSTAR™ Small Molecules
- GOSTAR™ TPD
- GOSTAR™ Large Molecules
Use GOSTAR™ to fuel compound screening, validate toxicity, and accelerate model training for AI/ML-driven drug discovery.
Excelra acquires BISC Global, creating an international bioinformatics powerhouse with an industry-leading platform and service offering.
Real-World Impact, Delivered
Indication expansion | 5 new trials
GI-focused data product using clinical, literature, and real-world evidence from 100,000+ samples led to 5 trials launched in <12 months.
Multi-Omics data platform | 60% faster insights
Enabled multiple teams to retrieve and analyze multi-omics data—legacy and new—on-demand.
AI-Driven toxicity modeling | 2x faster
GOSTAR™ datasets helped validate 5,000+ compounds, cutting model training time by 40%.
Scientific workflow automation | 20% productivity gain
Enterprise system integrated CTMS, ePRO, and LIMS to streamline OMICS request management.
Biologics candidate nomination | 25% quicker
Cross-functional decision-making accelerated by harmonizing epitope and immunogenicity data.
Regulatory affairs support | 50% faster response
LLM + RAG-based platform enabled fast, accurate responses to global health authority queries.
Whether you’re targeting a new indication, optimizing a lead, or predicting toxicity—Excelra delivers the data and digital infrastructure to drive impact.
Case study
30 alternate indications identified for six shelved compounds
We were engaged in helping our clients identify alternate indications for their assets. We developed an integrated strategy, providing our proprietary Global Repurposing Integrated Platform (GRIP) pipeline to perform in silico analysis and then validate the findings via wet lab experiments.
A total of six compounds were analyzed through the GRIP pipeline, generating insightful biological rationales for their use in new indications. The wet lab validation was then conducted using a multi-omics approach.
The combined analyses provided robust recommendations, which led to the identification of four repurposing opportunities and the expansion of the client’s portfolio.
Why Excelra
2x faster AI/ML model training with curated, contextualized datasets
25% quicker biologics candidate nomination through data pipeline harmonization
40% reduction in ADME-Tox model development timelines
60% acceleration in multi-omics data retrieval and analysis
50% faster regulatory response with GenAI-based document workflows
Ready to get more from data?
Tell us about your objectives. We’ll help get you there.
"*" indicates required fields
